Insulin signaling at target tissues is essential for growth, development and for normal homeostasis of glucose, fat and protein metabolism. Control over this process is therefore tightly regulated. It can be achieved by a negative feed-back control mechanism, whereby downstream components inhibit upstream elements along the insulin signaling pathway (auto regulation) or by signals from apparently unrelated pathways that inhibit insulin signaling thus leading to insulin resistance.
Preface Insulin resistance is a state in which the sensitivity of target cells to respond to ordinary levels of insulin is reduced. It plays a central role in the development of Type-2 diabetes, an emerging epidemic of the 21 st century. A variety of agents and conditions that induce insulin resistance such as TNF and free-fatty acids activate a number of protein kinases which target elements along the insulin signaling pathway. Some of these kinases phosphorylate the insulin receptor substrate (IRS)
proteins. Ser/Thr phosphorylation of IRS proteins inhibits their function, interferes with insulin signaling in a number of ways (Scheme I), thus leading to the development of an insulin resistance state.
In this article we will focus on the key molecular links between Ser/Thr phosphorylation of IRS proteins and the impairment in insulin signal transduction. We will outline the relations between inflammation; stress responses; the activation of IRS kinases and the induction of insulin resistance, and will propose a few directions for future studies in this field.
Insulin signaling
Insulin is one of the anabolic hormones which promotes proper metabolism, energy balance and maintenance of normal body weight (56) . Binding of insulin to its receptor activates the intrinsic Tyr-kinase activity of the receptor (IRK) which phosphorylates Tyr residues of target proteins such as the insulin receptor substrates (IRS-1 to 6), Shc proteins, Cbl, p60dok, APS and Gab-1 (92, 112) . Three major signaling pathways are propagated in response to activation of the IRK: the PI3K, the MAP Kinase and the Cbl/CAP pathway (92) . The MAP kinase cascade leads to enhanced cell growth, while the Cbl/CAP cascade mediates glucose transport through activation of the GTP-binding protein TC10 and the recruitment of the CIP4/Gappex-5 complex to the plasma membrane (73) . The phosphatidylinositol 3-kinase (PI3K) cascade is activated by the IRS proteins to trigger the metabolic functions of insulin. Tyr-phosphorylated IRS proteins, the major IR substrates, function as signaling scaffolds that propagate insulin action through binding of Src homology 2 (SH2)-domain containing proteins. These include the p85 regulatory subunit of PI3K, Nck, Fyn, Grb-2 and SHP2, which mediate various aspects of insulin action (58, 64) .
PI3K is one of the best characterized downstream effector of IRS proteins (14) . It associates with Tyr-phosphorylated IRS proteins following insulin stimulation and catalyzes the formation of phosphatidylinositol-3,4,5-trisphosphate, which stimulates phosphoinositide-dependent kinase (PDK1) activity and initiates the activation of its downstream effectors: protein kinase B (PKB, Akt), mTOR, p70S6 kinase (S6K1) as well as the atypical isoforms of PKC (PKC ), leading to glucose transport, protein and glycogen synthesis (8, 108) .
Control over insulin signaling can be achieved by autoregulation, whereby downstream components inhibit upstream elements (negative feedback control) (39, 80) . Alternatively, signals from apparently unrelated pathways can inhibit insulin signaling. The insulin receptor and the IRS proteins are targets for such feed-back control mechanisms (53, 72, 116, 117) , with phosphorylation of IRS proteins on Ser residues being a key step in these feed-back control processes (39, 80, 116, 117) . Many of the insulin-stimulated Ser/Thr kinases that are downstream effectors of IRS proteins serve as negative modulator of IRS proteins function. The activity of these kinases is blocked by inhibitors of the PI3K pathway, implicating Ser/Thr kinases, downstream of PI3K as potential IRS kinases (72). Interestingly, it is becoming apparent that inducers of insulin resistance such as tumor necrosis factor (TNF ), free fatty acids (FFAs) and cellular stress, make use of similar mechanisms by activating a set of IRS kinases that phosphorylate the IRS proteins and inhibit their function (109, 115) .
IRS kinases and Insulin resistance
Insulin resistance is defined as failure of ordinary levels of insulin to trigger its downstream metabolic actions and is closely associated with obesity and the development of type 2 diabetes (55). It is becoming clear that obesity promotes a state of chronic low-grade inflammation and insulin resistance (51, 52, 98) . This is attributed to the release from the adipose tissue of FFA, glycerol, hormones (e.g. leptin, adiponectin, ET-1), pro-inflammatory cytokines (e.g. TNF , IL-1 , IL-6) and additional products of macrophages that populate adipose tissue in obesity (27, 98, 109) .
It has been shown already a hundred years ago that high doses of salicylates lower glucose levels in diabetic patients implicating the involvement of inflammation in type-2 diabetes. Additionally, increased release of FFAs decreases insulin-mediated glucose transport in skeletal muscle and impairs suppression of glucose production by the liver, a characteristic of insulin resistance (3, 9, 47) .
Many inducers of insulin resistance activate IRS kinases that negatively regulate insulin signaling and action. The list of IRS kinases implicated in the development of insulin resistance is growing rapidly, concomitant with the list of potential Ser/Thr phosphorylation sites in IRS proteins (22, 117) . Recent studies have focused on IRS-1 as a major target for IRS kinases (22) . However, it is now becoming evident that IRS-2 serve as a target as well (40, 97, 99 Inducers of insulin resistance also activate PKC-, a novel-type PKC. PKC- is activated upon increased content of intramuscular long-chain fatty acyl-CoA. An increase in PKC-activity occurs concomitantly with a decrease in insulin-stimulated Tyr-phosphorylation of IRS-1 and a reduction in glucose transport (38, 113) . PKC--deficient mice are protected against fat-induced defects in insulin signaling (e.g. reduced insulin-stimulated Tyr phosphorylation of IRS-1 and glucose uptake) in skeletal muscle, further supporting the role of PKC-in mediating fatty acidinduced insulin resistance (60) . Notably, in the latter study no direct evidences on Ser phosphorylation of IRS-1 or activation of other Ser/Thr kinases such as IKK-or JNK were provided. The notion that PKC-plays a role in fatty acid-mediated insulin resistance was challenged by the findings that transgenic mice with muscle-specific expression of a dominantnegative PKC-have shown age-and obesity-associated glucose intolerance implicating PKC-as a protective rather than a negative regulator of insulin function (96) . These discrepant findings may be due to the different technical approaches that were used. For example, a dominant negative PKCcould bind (and titrate out) proteins necessary for the proper function of other PKC isoforms. At the molecular level, PKC-, a known activator of IKK-and JNK (60, 101) , may attenuate insulin signaling directly or via the activation of these IRS kinases. Ser1101 (68) and Ser307 (113) were suggested as potential target sites of PKC-in IRS-1.
Autologous vs. heterologous feed-back mechanisms can sometimes act in antagonistic manner. This is exemplified by Glycogen synthase kinase-3 (GSK-3  an important mediator of insulin signaling, which phosphorylates IRS proteins on Ser residues to attenuate insulin actions.
Ser332 in IRS-1 is a potential GSK-3 phosphorylation site for with Ser336 being the priming site (69) . GSK-3 activity is inhibited by insulin upon its phosphorylation by insulin-stimulated PKB (19) . In contrast, inducers of insulin resistance stimulate the activity of GSK-3 (18, 45) , which is elevated in diabetic tissues (26). Accordingly, GSK-3 KO mice display enhanced glucose and insulin sensitivity accompanied by reduced fat mass. Hepatic insulin signaling in these mice is increased, and so is the IRS-1 expression (76). Moreover, a reduction in GSK-3 in human muscle cells results in an increase in insulin-stimulated glucose uptake, glycogen synthase activity and IRS-1 expression (16), while treatment with GSK-3 inhibitors enhances insulin actions in vitro and in vivo (17, 85) . In contrast, insulin-mediated phosphorylation of PKB and glycogen synthase were similar in skeletal muscle from both WT and GSK-3 KO mice which may indicate different roles for GSK-3 in mice vs. human (16, 76) . Similarly, McManus et al (77) , have generated homozygous knock in mice of constitutive active (CA) GSK-3 , GSK-3 or GSK-3 . Although GSK-3 had a major role in regulating glycogen synthase activity in muscle of CA GSK-3 knock in mice, these animals were not diabetic and their insulin stimulated PKB activation and glucose uptake were not changed. These findings cast a certain doubt as to the critical role of GSK-3 in the attenuation of insulin signaling at least in mouse models, although constitutive activation of GSK-3 under normal conditions (e.g. regular diet, Low BMI) might be necessary, but it is insufficient to promote systemic insulin resistance. Hence, with respect to GSK-3, insulin acts to prevent its action as an IRS kinase, while heterologous signaling cascades activate it. S6K1-deficient mice remain sensitive to insulin owing to apparent loss of a negative feedback loop from S6K1 to IRS-1, which blunts Ser307 and Ser636/639 phosphorylation; sites involved in insulin resistance (105) . In a recent publication, Ser1101 was identified as another S6K1 site in IRS-1, the phosphorylation of which is increased upon nutrient overload and obese setting. Consistent with these findings, in a short term in vivo study, in which insulin resistance was introduced by infusion of a high concentration of amino acids in humans, rapamycin, an mTOR inhibitor, improves insulin actions (62) . On the contrary, long-term treatment with rapamycin increased rather than decreased the insulin resistance of P. obesus, that was induced by high energy diet (32) . This could be attributed to the increased activity of stress-response kinases in muscle and islets. Hence, either sustained activation of the mTOR/S6K1 pathways or their inhibition could result in insulin resistance albeit through different mechanisms.
ii. Interference with IRS-IR complex formation mediated by the PH domain
An additional Ser site at the C-terminus of IRS-1 is Ser789. Ser789 was shown to be a target for the salt inducible kinase 2 (SIK2, a novel member of the AMPK family) in adipose cells (50) .
The activity and content of SIK2 are elevated in white adipose tissue of db/db diabetic mice, Of note, phosphorylation of Ser307 might be necessary, but it is insufficient to promote IRS-1 degradation. In accordance with this conclusion we could show that insulin-induced degradation of a mutated form of IRS-1 was significantly reduced even when Ser307 phosphorylation remained unchanged (10) . We could further show that elimination of an entire Ser/Thr-rich domain of IRS-1, proximal to its PTB domain protects IRS-1 from chronic-insulin induced degradation (10).
Collectively, these findings support the notion that Ser/Thr phosphorylation is involved in insulinstimulated IRS-1 degradation.
v. Positive regulation of IRS-1 by insulin-mediated Ser phosphorylation
Tyr These findings suggest that upon acute insulin stimulation, IRS-1 is phosphorylated on Tyr residues to propagate insulin signaling, a reaction accompanied by its phosphorylation on Ser residues which serve as 'guardians' of the phosphorylated Tyr residues namely, by inhibiting Tyr phosphatases and/or phosphorylation at 'inhibitory' Ser sites. Phosphorylation of IRS-1 on these 'inhibitory' Ser sites then commences with a delayed onset.
Phosphorylation of IRS proteins in human subjects
Most information related to the regulation of IRS proteins function is based on studies in cell cultures and in mouse models. Still, accumulating evidence of in vivo studies in humans supports the concept that increased Ser/Thr phosphorylation of IRS proteins might turn subjects prone to the development of insulin resistance (80) . The IRS kinases involved seem to be those already implicated as negative regulators of insulin signaling. In a recent study, using skeletal muscle biopsies from 11 humans, the mTOR/S6K pathway was shown to negatively modulate glucose metabolism under nutrient abundance (62) . In agreement with previous studies, phosphorylation of Ser312 and 636 of IRS-1 was implicated as part of this negative regulation (62, 102) . Increased phosphorylation of Ser 636 of IRS-1 was observed in myotubes of patients with type 2 diabetes. Inhibition of ERK1/2 with PD98059 reduced this phosphorylation, thereby implicating ERK1/2 in the phosphorylation of Ser636 in human muscle (11) .
To unveil the importance of phosphorylated Ser/Thr residues of human IRS-1, Yi et. al.
adopted a mass spectrometry approach (111) . Although this system may suffer some drawbacks, a number of the potential Ser/Thr residues involved in the regulation of IRS proteins function could be identified. More than twenty Ser residues of IRS-1 were found to undergo insulin-stimulated phosphorylation in human muscle biopsies, three of which were newly identified sites: Thr495, Ser527 and Ser1005 (human numbering). This report validates previous in vitro and in vivo studies in animal models and suggests that the same strategy could be employed to identify phosphorylated Ser/Thr sites under conditions of insulin resistance, obesity or type 2 diabetes.
Ser phosphorylation of IRS proteins-is it an array phenomenon or an event confined to few selected Ser sites Data collected so far suggests that an array of Ser/Thr phosphorylation sites of IRS-1 attenuates insulin signaling, rather than phosphorylation of single selected sites (Scheme 2). Ser/Thr phosphorylation disrupts at least three interactions of IRS-1: with the plasma membrane; the receptor; or its downstream effectors. Therefore, many of the potential Ser residues distributed along the IRS proteins could be involved. IRS-1 contains more than 70 Ser residues at potential consensus phosphorylation sites and each signal could induce the phosphorylation of a different set of residues. Hence, numerous optional phosphorylation combinations are possible. In order to obtain an accurate analysis, all potential sites phosphorylated in response to various stimuli should be examined as opposed to analysis of a small number of residues limited by availability of phospho-specific antibodies. It has already been shown that quite a number of Ser residues undergo phosphorylation upon insulin treatment in human muscle biopsies (111) 
Specificity versus Flexibility
The identity of the Ser residues, the phosphorylation of which results in specific alteration in IRS proteins structure and function is still poorly understood. Ser 307 is considered to be involved in IRS-1 degradation (37), while we have shown that deletion of a Ser-rich domain of IRS-1 protects it from insulin-stimulated degradation despite the fact that this IRS-1 mutant is still highly phosphorylated on Ser307 (10) . We could also show that mutation of seven Ser sites of IRS-1, different from Ser307, confers upon the mutant protein protection from the inhibitory action of sustained insulin treatment or the inhibitory effects of pro-inflammatory cytokines (46, 71) . These findings support the notion that phosphorylation of IRS proteins at selected domains (e.g. their PTB domain), rather than phosphorylation of selected sites (e.g. Ser307) is required to inhibit IRS proteins function. Accordingly, mutations of seven Ser residues within a given domain confer stronger protection from IRS kinases than mutations of three or a single residue (46, 71) . This conclusion is supported by a recent study that made use of muscle specific knock-in mice which express a mutant IRS-1 where three serine residues were replaced by alanine (Ser302, 307, 612) (79) . The transgenic mice were partially protected from fat-induced insulin resistance. These studies therefore indicate that mutation of a number of Ser/Thr phosphorylation sites rather than single sitespecific mutation sensitizes IRS-1 and protects it from negative feed-back regulation of insulin signaling. The issue of dominance should also be considered, namely, what happens when an array of 'positive' and 'negative' Ser sites is mutated. For example, we could show that when such 'mixed' mutation is performed the net effect is potentiation of insulin signaling (46, 71) , suggesting the dominance of 'inhibitory' Ser sites over the 'stimulatory' sites in this particular case.
Altogether, these findings indicate the existence of a cross talk between Ser phosphorylation sites and suggest that the overall phosphorylation pattern dictates IRS-1 functions.
Ser The array of Ser/Thr phosphatases that dephosphorylate the different Ser residues and resets the system to its basal state have not been elucidated. It is only conceivable to assume that the activity of these phosphatases is regulated to no lesser extent than the activity of the IRS kinases.
Several strategies could be applied to address these questions. The fast-developing field of mass spectrometry now enables the identification of arrays of Ser sites of IRS proteins that are subjected to phosphorylation under in vivo conditions. Samples of human tissues, processed to isolate their IRS proteins and subject them to such analysis could be most insightful in defining the extent of phosphorylation of each site under physiological or pathological conditions. 
